TD Cowen maintains USD 30.00 target for BioCryst Pharmaceuticals stock
Published on 10/24/2026 at 18:50 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and reporting date
- TD Cowen maintained a USD 30.00 target for BioCryst on October 21, 2026.
- The FDA approved 150 mg ORLADEYO granules for eligible patients on October 21, 2026.
- BioCryst stock costs EUR 6.83 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.
- BioCryst is scheduled to report third-quarter 2026 results on November 4, 2026.
BioCryst Pharmaceuticals (US09058V1035) remains under a USD 30.00 target from TD Cowen, which maintained its Buy rating on October 21, 2026, according to Moomoo News. BioCryst stock was at EUR 6.83 at Lang & Schwarz on October 24, 2026 at 1:04 p.m. CEST.
ORLADEYO expands its delivery options
The FDA approved BioCryst's 150 mg ORLADEYO oral-granule formulation for adults and adolescents aged 12 and older on October 21, 2026. The approval gives eligible patients an alternative to capsules for once-daily hereditary angioedema prevention, as MarketScreener reported that day.
The product update matters because ORLADEYO is BioCryst's commercial foundation. The company describes the medicine as an oral, once-daily treatment, while its pipeline includes additional therapies for rare diseases.
Price position and operating scale
BioCryst's Nasdaq price closed at USD 7.78 on October 23, 2026, while its 52-week range was USD 6.23 to USD 11.22 and volume reached 2,745,636 shares. The Lang & Schwarz euro quotation therefore stood within the current market frame, although the currencies are not directly comparable.
BioCryst had a market capitalization of USD 1.95 billion as of October 23, 2026. The company operates in healthcare biotechnology and focuses on orally administered and injectable treatments for rare diseases.
Revenue growth meets a competitive test
BioCryst reported second-quarter 2026 revenue of USD 218.3 million, up 34.00 percent year over year, according to Insider Monkey. The report said USD 55.7 million came from licensing revenue, while ORLADEYO generated USD 158.2 million and increased 1.00 percent on a reported basis.
That mix leaves recurring ORLADEYO demand as the key operating question. BioCryst expects 2026 ORLADEYO revenue of USD 625.0 million to USD 645.0 million within total revenue guidance of USD 690.0 million to USD 715.0 million, figures reported by Insider Monkey on October 15, 2026.
BioCryst is scheduled to publish third-quarter 2026 results on November 4, 2026, according to MarketScreener. That release should help investors separate licensing revenue from the underlying commercial trend.
What comes next for BioCryst
TD Cowen's USD 30.00 target places emphasis on BioCryst's development pipeline as well as its established product. The FDA decision broadens ORLADEYO's administration options, while the second-quarter revenue mix shows why future results will be judged on the durability of recurring sales.
The further course of trading is shown by the continuously updated real-time quote of BioCryst Pharmaceuticals stock.
BioCryst Pharmaceuticals at a glance
- Company: BioCryst Pharmaceuticals, Inc.
- ISIN: US09058V1035
- Ticker: BCRX
- Primary exchange: NASDAQ
- Price Lang & Schwarz (as of October 24, 2026, 1:04 p.m. CEST): EUR 6.83
- Market capitalization: USD 1.95 billion (as of October 23, 2026)
- 52-week range: USD 6.23-11.22 (as of October 23, 2026)
- Sector / Industry: Healthcare / Biotechnology
- Next earnings date: November 4, 2026
Market context: Market report S&P 500.
